Last reviewed · How we verify
Allogenic MSCs
Allogeneic mesenchymal stem cells (MSCs) exert immunomodulatory and regenerative effects by secreting anti-inflammatory cytokines and promoting tissue repair.
Allogeneic mesenchymal stem cells (MSCs) exert immunomodulatory and regenerative effects by secreting anti-inflammatory cytokines and promoting tissue repair. Used for Graft-versus-host disease (GVHD), Tissue repair and regeneration.
At a glance
| Generic name | Allogenic MSCs |
|---|---|
| Sponsor | Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León |
| Drug class | Cell therapy |
| Modality | Small molecule |
| Therapeutic area | Regenerative Medicine / Immunology |
| Phase | Phase 3 |
Mechanism of action
Allogeneic MSCs are multipotent stromal cells derived from donor sources that migrate to damaged tissues and modulate the immune response through paracrine signaling, reducing inflammation and promoting endogenous repair mechanisms. These cells can differentiate into various cell types and secrete bioactive molecules including IL-10, TGF-β, and other factors that suppress pro-inflammatory responses and support tissue regeneration.
Approved indications
- Graft-versus-host disease (GVHD)
- Tissue repair and regeneration
Common side effects
- Infusion-related reactions
- Infection
- Immunogenicity
Key clinical trials
- Phase 1 Study of VELGRAFT, a Living Cellular Construct, in the Management of Chronic Diabetic Foot Ulcers Which Have Attained Granulation Tissue (PHASE1)
- "An Intermediate Size Patient Population Expanded Access Protocol to Evaluate the Safety and Efficacy of Allogeneic HB-adMSCs (Hope Biosciences - Adipose Derived Mesenchymal Stem Cells) for the Treatment of Multiple System Atrophy."
- Mesenchymal Stem Cell Therapy (MSCs) and Conditioned Medium Therapy for Osteoartrithis (PHASE1, PHASE2)
- Umbilical Cord Mesenchymal Stem Cell for Liver Cirrhosis Patient Caused by Hepatitis B (PHASE1, PHASE2)
- Interferon γ-Primed Mesenchymal Stromal Cells as Prophylaxis for Acute Graft v Host Disease (PHASE1)
- Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cell Therapy in Diabetic Nephropathy Patients: A Clinical Trial (PHASE1, PHASE2)
- Adia MED of Winter Park LLC Autism Spectrum Disorder Research Study (PHASE1, PHASE2)
- Phase 2 Trial of Mesenchymal Stem Cells in Systemic Lupus Erythematosus (MiSLE) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: